Regeneron Pharmaceuticals’ (NASDAQ:REGN) “Outperform” Rating Reaffirmed at Leerink Swann
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “outperform” rating reiterated by research analysts at Leerink Swann in a research report issued to clients and investors on Wednesday. They currently have a $580.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $573.00. Leerink Swann’s target price would suggest a potential upside of 23.54% from the company’s current price.
Several other research firms have also issued reports on REGN. Jefferies Group LLC restated a “hold” rating and issued a $357.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 12th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 target price for the company. in a report on Monday, April 24th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 target price for the company in a report on Thursday, April 27th. BMO Capital Markets restated a “hold” rating and issued a $421.00 target price (up previously from $412.00) on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Finally, Cowen and Company restated a “hold” rating and issued a $380.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $479.83.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 469.68 on Wednesday. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a 50-day moving average of $499.39 and a 200 day moving average of $422.69. The company has a market capitalization of $49.58 billion, a P/E ratio of 56.86 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the company posted $2.82 EPS. The business’s revenue was up 21.2% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post $14.84 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/09/regeneron-pharmaceuticals-nasdaqregn-outperform-rating-reaffirmed-at-leerink-swann.html.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $482.55, for a total transaction of $482,550.00. Following the completion of the sale, the director now directly owns 14,000 shares in the company, valued at approximately $6,755,700. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at $1,350,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,396 shares of company stock valued at $28,484,734. Company insiders own 10.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in REGN. BlackRock Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Wellington Management Group LLP boosted its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares in the last quarter. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock valued at $1,984,630,000 after buying an additional 199,975 shares in the last quarter. State Street Corp boosted its position in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its position in Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock valued at $749,145,000 after buying an additional 41,630 shares in the last quarter. Institutional investors and hedge funds own 66.70% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.